Clinical Trial Update: Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating daratumumab for chemotherapy-refractory minimal residual disease in T-cell acute lymphoblastic leukemia is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: T-cell Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING